Vioxx Hearing Witnesses Push For Independent Drug Safety Office

The proposal to create an independent Office of Drug Safety at FDA may be gaining momentum, following a congressional hearing reviewing FDA's handling of Merck's Vioxx (rofecoxib)

More from Archive

More from Pink Sheet